Abcellera Biologics Debt 2025

Abcellera Biologics Aktienanalyse

What does Abcellera Biologics do?

Abcellera Biologics Inc. is a leading biotechnology company specializing in the discovery of antibodies and the identification of therapies for serious diseases. The company was founded in Vancouver, Canada in 2012 and has since become a major player in the biotechnology field. It has formed numerous significant partnerships with large pharmaceutical companies in recent years and works closely with leading universities and research institutions worldwide. Abcellera Biologics Inc. follows a new, innovative business model that focuses on the discovery of antibodies through the application of cutting-edge technologies, data science, and machine learning. The company has developed a revolutionary technology platform called "Microfluidic Drop-based Technology" that is capable of discovering thousands of antibodies within just a few weeks. This technology allows for the rapid and efficient discovery of antibodies that can be used in the treatment of serious diseases. Abcellera Biologics Inc. is divided into several divisions that focus on antibody discovery, therapy development, collaborations with pharmaceutical companies, and services. Antibody discovery is carried out through years of research and development using state-of-the-art technologies and methods. Therapy development includes preclinical and clinical development of therapeutic products and conducting clinical trials. Abcellera Biologics Inc. works closely with leading pharmaceutical companies in the industry to develop new therapies and discover antibodies. The company has already formed numerous partnerships with major pharmaceutical companies such as Pfizer, Sanofi, GlaxoSmithKline, AbbVie, and Biogen. Another important focus of Abcellera Biologics Inc. is providing services in the field of antibody development. The company has extensive expertise in antibody discovery and therefore offers services to other companies. This allows other companies to benefit from Abcellera Biologics Inc.'s unique technology platform and top-notch capabilities. Abcellera Biologics Inc.'s product portfolio includes various antibody therapies targeting the treatment of specific diseases. One of the company's most promising products is the "LY-CoV555" antibody therapy used for COVID-19. This therapy was developed in collaboration with Eli Lilly and is currently being tested in clinical trials. Overall, Abcellera Biologics Inc. has become a leading company in the biotechnology industry. Its focus on antibody discovery through state-of-the-art technologies and data-driven methods, as well as successful collaborations with major pharmaceutical companies, makes it an important player in the industry. Abcellera Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Abcellera Biologics's Debt Structure

Abcellera Biologics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Abcellera Biologics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Abcellera Biologics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Abcellera Biologics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Abcellera Biologics stock

What is the debt of Abcellera Biologics this year?

Abcellera Biologics has a debt level of -156.33 USD this year.

What was the debt of Abcellera Biologics compared to the previous year?

The debt of Abcellera Biologics has increased by 17.26% compared to the previous year increased.

What are the consequences of high debt for investors in Abcellera Biologics?

High debt can pose a risk for investors of Abcellera Biologics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Abcellera Biologics?

Low debt means that Abcellera Biologics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Abcellera Biologics affect the company?

An increase in debt of Abcellera Biologics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Abcellera Biologics affect the company?

A reduction in debt of Abcellera Biologics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Abcellera Biologics?

Some factors that can influence the debt of Abcellera Biologics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Abcellera Biologics so important for investors?

The debts of Abcellera Biologics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Abcellera Biologics take to change the debt?

To change the debt, Abcellera Biologics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Abcellera Biologics pay?

Over the past 12 months, Abcellera Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abcellera Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of Abcellera Biologics?

The current dividend yield of Abcellera Biologics is .

When does Abcellera Biologics pay dividends?

Abcellera Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abcellera Biologics?

Abcellera Biologics paid dividends every year for the past 0 years.

What is the dividend of Abcellera Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abcellera Biologics located?

Abcellera Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcellera Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcellera Biologics from 5/9/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/9/2025.

When did Abcellera Biologics pay the last dividend?

The last dividend was paid out on 5/9/2025.

What was the dividend of Abcellera Biologics in the year 2024?

In the year 2024, Abcellera Biologics distributed 0 USD as dividends.

In which currency does Abcellera Biologics pay out the dividend?

The dividends of Abcellera Biologics are distributed in USD.